[1] Poulose V.Severe community-acquired pneumonia requiring intensive care: a study of 80 cases from Singapore. Singapore Med J, 2008, 49(6): 458-461. [2] Restrepo MI, Mortensen EM, Velez JA, et al.A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest, 2008,133(3): 610-617. [3] Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007,44 Suppl 2:S27-72. [4] Chalmers JD, Taylor JK, Mandal P, et al.Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis, 2011,53(6): 503-511. [5] Restrepo MI, Jorgensen JH, Mortensen EM, et al.Severe community-acquired pneumonia: current outcomes, epidemio-logy, etiology, and therapy. Curr Opin Infect Dis, 2001,14(6): 703-709. [6] Zilberberg MD, Shorr AF. Healthcare-associated pneumonia: the state of evidence to date. Curr Opin Pulm Med, 2011,17(3): 142-147. [7] Angus DC, Marrie TJ, Obrosky DS, et al.Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med, 2002,166(5): 717-723. [8] Osler W. The principles and practice of medicine:designed for the use of practitioners and students of medicine. 4th ed. New York: D. Appleton and company,1912. [9] Taneja C, Haque N, Oster G, et al.Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med, 2010,5(9):528-534. [10] Ramsey C, Kumar A. H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care, 2011,17(1): 64-71. [11] Labelle AJ, Arnold H, Reichley RM,et al.A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest, 2010,137(5): 1130-1137 [12] Falguera M, Trujillano J, Caro S,et al.A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis, 2009,49(3): 409-416. [13] Shimada T, Noguchi Y, Jackson JL,et al.Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest, 2009,136(6): 1576-1585. [14] Chastre J, Trouillet JL, Combes A, et al.Diagnostic techniques and procedures for establishing the microbial etiology of ventilator-associated pneumonia for clinical trials: the pros for quantitative cultures. Clin Infect Dis, 2010,51 (Suppl 1): S88-92. [15] Johansson N, Kalin M, Tiveljung-Lindell A, et al.Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis, 2010,50(2): 202-209. [16] Chalmers JD, Singanayagam A, Akram AR,et al.Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax, 2010, 65(10): 878-883 [17] Chalmers JD, Singanayagam A, Akram AR,et al. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother, 2011, 66(2): 416-423. [18] Francis NA, Cals JW, Butler CC, et al. Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care. Prim Care Respir J, 2012,21(1): 65-70. [19] Ewig S, Bauer T, Richter K, et al.Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J, 2013, 41(4): 917-922. [20] Marti C, Garin N, Grosgurin O, et al.Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care, 2012, 16(4): 141. [21] Berg P, Lindhardt B. The role of procalcitonin in adult patients with community-acquired pneumonia-a systematic review. Dan Med J, 2012, 59(3):A4357. [22] Christ-Crain M, Stolz D, Bingisser R,et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med, 2006,174(1): 84-93. [23] Lepper PM, Ott S, Nüesch E,et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ, 2012,28(344):3397. [24] Bello S, Lasierra AB, Mincholé E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J, 2012,39(5): 1144-1155. [25] Martin-Loeches I, Lisboa T, Rodriguez A,et al.Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med, 2010,36(4): 612-620. [26] American Thoracic Society, Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005,171(4): 388-416. [27] Taccone FS, Laterre PF, Spapen H,et al. Revisiting the loa-ding dose of amikacin for patients with severe sepsis and septic shock. Crit Care, 2010, 14(2): 53. [28] Wunderink RG. Surrogate markers and microbiologic end points. Clin Infect Dis, 2010,51 (Suppl 1): S126-130. [29] De Pascale G, Bello G, Antonelli M.Steroids in severe pneumonia: a literature review. Minerva Anestesiol, 2011,77(9): 902-910. [30] Woodhead M, Blasi F, Ewig S,et al.Guidelines for the ma-nagement of adult lower respiratory tract infections-full version. Clin Microbiol Infect, 2011,17 (Suppl 6): E1-59. [31] Torres A, Ewig S, Lode H, et al. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med, 2009,35(1): 9-29. [32] Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care, 2008,12 (Suppl 6): S2. [33] Briel M, Meade M, Mercat A,et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA, 2010,303(9): 865-873. [34] Sud S, Friedrich JO, Taccone P, et al. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med, 2010,36(4): 585-599. [35] Peek GJ, Mugford M, Tiruvoipati R, et al.Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 2009,374(9698): 1351-1363. [36] Noah MA, Peek GJ, Finney SJ, et al.Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA, 2011,306(15): 1659-1668. |